A novel small molecule activator of the integrated stress response kinase GCN2 shows potent preclinical antitumor activity as monotherapy and in combination with standard of care agentsEUROPEAN JOURNAL OF CANCERIF7.12024-10-010PRE
DCC-3084, a brain penetrant RAF dimer inhibitor, broadly inhibits BRAF class I, II, and III alterations leading to growth inhibition of intracranially implanted tumors in preclinical modelsCANCER RESEARCHIF16.62024-03-220PRE
DP-9024, an investigational small molecule modulator of the integrated stress response kinase GCN2, synergizes with asparaginase therapy in leukemic tumorsCANCER RESEARCHIF16.62023-04-040PRE
DP-9149, an investigational small molecule modulator of the Integrated Stress Response kinase GCN2, pre-clinically causes solid tumor growth inhibition as a single agent and regression in combination with standard of care agentsCANCER RESEARCHIF16.62023-04-040PRE
DP-9024, an investigational small molecule modulator of the Integrated Stress Response kinase PERK, causes B-cell cancer growth inhibition as single agent and in combination with standard-of-care agentsCANCER RESEARCHIF16.62023-04-040PRE
Dimerization-induced activation of the integrated stress response kinase PERK by an investigational small molecule modulator, DP-9024CANCER RESEARCHIF16.62023-04-040PRE
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向